128 related articles for article (PubMed ID: 10450984)
21. Heterocycle-peptide hybrid compounds. Aminotriazole-containing agonists of the thrombin receptor (PAR-1).
McComsey DF; Hawkins MJ; Andrade-Gordon P; Addo MF; Oksenberg D; Maryanoff BE
Bioorg Med Chem Lett; 1999 May; 9(10):1423-8. PubMed ID: 10360749
[TBL] [Abstract][Full Text] [Related]
22. Identification of the minimum PAR4 inhibitor pharmacophore and optimization of a series of 2-methoxy-6-arylimidazo[2,1-b][1,3,4]thiadiazoles.
Temple KJ; Duvernay MT; Maeng JG; Blobaum AL; Stauffer SR; Hamm HE; Lindsley CW
Bioorg Med Chem Lett; 2016 Nov; 26(22):5481-5486. PubMed ID: 27777004
[TBL] [Abstract][Full Text] [Related]
23. Discovery and initial structure-activity relationships of trisubstituted ureas as thrombin receptor (PAR-1) antagonists.
Barrow JC; Nantermet PG; Selnick HG; Glass KL; Ngo PL; Young MB; Pellicore JM; Breslin MJ; Hutchinson JH; Freidinger RM; Condra C; Karczewski J; Bednar RA; Gaul SL; Stern A; Gould R; Connolly TM
Bioorg Med Chem Lett; 2001 Oct; 11(20):2691-6. PubMed ID: 11591503
[TBL] [Abstract][Full Text] [Related]
24. Potent non-peptide thrombin receptor antagonists.
Chackalamannil S; Ahn HS; Xia Y; Doller D; Foster C
Curr Med Chem Cardiovasc Hematol Agents; 2003 Mar; 1(1):37-45. PubMed ID: 15317289
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor.
Andrade-Gordon P; Maryanoff BE; Derian CK; Zhang HC; Addo MF; Darrow AL; Eckardt AJ; Hoekstra WJ; McComsey DF; Oksenberg D; Reynolds EE; Santulli RJ; Scarborough RM; Smith CE; White KB
Proc Natl Acad Sci U S A; 1999 Oct; 96(22):12257-62. PubMed ID: 10535908
[TBL] [Abstract][Full Text] [Related]
26. Synthesis, biological evaluation and molecular docking studies of 2-piperazin-1-yl-quinazolines as platelet aggregation inhibitors and ligands of integrin αIIbβ3.
Krysko AA; Kornylov AY; Polishchuk PG; Samoylenko GV; Krysko OL; Kabanova TA; Kravtsov VCh; Kabanov VM; Wicher B; Andronati SA
Bioorg Med Chem Lett; 2016 Apr; 26(7):1839-43. PubMed ID: 26912112
[TBL] [Abstract][Full Text] [Related]
27. Synthesis of novel peptide inhibitors of thrombin-induced platelet activation.
Burke FM; Warnock M; Schmaier AH; Mosberg HI
Chem Biol Drug Des; 2006 Nov; 68(5):235-8. PubMed ID: 17177882
[TBL] [Abstract][Full Text] [Related]
28. Antiplatelets activity of some xanthone derivatives.
Rajtar G; Zółkowska D; Kleinrok Z; Marona H
Acta Pol Pharm; 1999; 56(4):319-24. PubMed ID: 10635366
[TBL] [Abstract][Full Text] [Related]
29. Protease activated receptor 4 (PAR4) antagonists: Research progress on small molecules in the field of antiplatelet agents.
Liu S; Li S; Yuan D; Wang E; Xie R; Zhang W; Kong Y; Zhu X
Eur J Med Chem; 2021 Jan; 209():112893. PubMed ID: 33049608
[TBL] [Abstract][Full Text] [Related]
30. The PAR1 antagonist, SCH79797, alters platelet morphology and function independently of PARs.
Lee H; Hamilton JR
Thromb Haemost; 2013 Jan; 109(1):164-7. PubMed ID: 23093354
[No Abstract] [Full Text] [Related]
31. Analysis of anti-PDE3 activity of 2-morpholinochromone derivatives reveals multiple mechanisms of anti-platelet activity.
Abbott BM; Thompson PE
Bioorg Med Chem Lett; 2006 Feb; 16(4):969-73. PubMed ID: 16290931
[TBL] [Abstract][Full Text] [Related]
32. Polycyclic N-heterocyclic compounds. Part 62: Reaction of N-(quinazolin-4-yl)amidine derivatives with hydroxylamine hydrochloride and anti-platelet aggregation activity of the products.
Okuda K; Zhang YX; Ohtomo H; Hirota T; Sasaki K
Chem Pharm Bull (Tokyo); 2010 Mar; 58(3):369-74. PubMed ID: 20190443
[TBL] [Abstract][Full Text] [Related]
33. Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets.
Covic L; Gresser AL; Kuliopulos A
Biochemistry; 2000 May; 39(18):5458-67. PubMed ID: 10820018
[TBL] [Abstract][Full Text] [Related]
34. A comparative SAR study of thrombin receptor derived non peptide mimetics: importance of phenyl/guanidino proximity for activity.
Alexopoulos K; Matsoukas J; Tselios T; Roumelioti P; Mavromoustakos T; Holada K
Amino Acids; 1998; 15(3):211-20. PubMed ID: 9871500
[TBL] [Abstract][Full Text] [Related]
35. Aptamer inhibits degradation of platelet proteolytically activatable receptor, PAR-1, by thrombin.
Boncler MA; Koziolkiewicz M; Watala C
Thromb Res; 2001 Nov; 104(3):215-22. PubMed ID: 11672764
[TBL] [Abstract][Full Text] [Related]
36. The novel and orally active thrombin receptor antagonist E5555 (Atopaxar) inhibits arterial thrombosis without affecting bleeding time in guinea pigs.
Kogushi M; Matsuoka T; Kawata T; Kuramochi H; Kawaguchi S; Murakami K; Hiyoshi H; Suzuki S; Kawahara T; Kajiwara A; Hishinuma I
Eur J Pharmacol; 2011 Apr; 657(1-3):131-7. PubMed ID: 21300059
[TBL] [Abstract][Full Text] [Related]
37. Monamidocin, a novel fibrinogen receptor antagonist. II. Biological activity and structure-activity relationships.
Kamiyama T; Satoh T; Umino T; Katoh H; Uemura F; Nakamura Y; Yokose K
J Antibiot (Tokyo); 1995 Nov; 48(11):1226-33. PubMed ID: 8557561
[TBL] [Abstract][Full Text] [Related]
38. Peptide-derived protease-activated receptor-1 (PAR-1) antagonists.
Seiler SM; Bernatowicz MS
Curr Med Chem Cardiovasc Hematol Agents; 2003 Mar; 1(1):1-11. PubMed ID: 15317287
[TBL] [Abstract][Full Text] [Related]
39. 2-(2-Br-phenyl)-8-methoxy-benzoxazinone (HPW-RX2), a direct thrombin inhibitor with a suppressive effect on thromboxane formation in platelets.
Wu CC; Wang TW; Wang WY; Hsieh PW; Wu YC
Eur J Pharmacol; 2005 Dec; 527(1-3):37-43. PubMed ID: 16313903
[TBL] [Abstract][Full Text] [Related]
40. The serine protease granzyme A does not induce platelet aggregation but inhibits responses triggered by thrombin.
Suidan HS; Clemetson KJ; Brown-Luedi M; Niclou SP; Clemetson JM; Tschopp J; Monard D
Biochem J; 1996 May; 315 ( Pt 3)(Pt 3):939-45. PubMed ID: 8645180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
